Get notified when INNV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Civil Investigative Demand (worsened) — The company recorded a $37.0 million litigation accrual related to the 2021 and 2022 DOJ civil investigative demands, whereas the prior year stated it was unable to estimate possible losses.
InnovAge swings to operating income on 15.9% revenue growth, but $989.7M DOJ accrual and Medicaid cuts loom
Filed September 9, 2026 · Period ending June 30, 2026 · Compared to 10-K Sep 9, 2025 · ~1 min read
Key Changes
-
high
Revenue rose 15.9% to $989.7M, and operating income swung from a loss, driven by higher capitation rates and enrollment.
MD&A verify on EDGAR → -
high
Net loss narrowed, but a litigation expense increase, including a accrual for DOJ civil investigative demands, weighed on results.
MD&A / Notes view on EDGAR → -
high
California paused all new PACE center applications for at least two years, and Colorado Medicaid premium rates are expected to decrease retroactively to July 1, 2026.
MD&A verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade INNV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 11, 2026 · How we verify